托法替布单药治疗在银屑病关节炎患者甲氨蝶呤撤药后的随机对照研究
OPAL Balance 子研究纳入已稳定接受托法替布5mg每日两次联合甲氨蝶呤≥24个月的银屑病关节炎患者,随机分为托法替布+安慰剂(撤甲氨蝶呤)或托法替布+继续甲氨蝶呤。6个月时两组PASDAS和HAQ-DI变化差异无统计学意义,安全性和实验室变化总体相似,但甲氨蝶呤组肝酶升高更常见。
要点
- 稳定联合治疗的银屑病关节炎患者撤除甲氨蝶呤后6个月内疾病活动度和功能无临床显著恶化
- 撤药组与继续甲氨蝶呤组不良事件、特殊关注不良事件和实验室变化总体相似
- 继续甲氨蝶呤组肝酶升高更常见,撤药组报告1例症状加重(银屑病关节病)
核心结论
- 部分稳定接受托法替布5mg每日两次联合甲氨蝶呤的银屑病关节炎患者可能可以在无临床显著疾病活动度和安全性变化的情况下停用甲氨蝶呤。
研究设计与样本
- OPAL Balance长期扩展研究的12个月随机、双盲、安慰剂对照甲氨蝶呤撤药子研究,涉及50个中心、14个国家。
- 患者1:1盲法随机接受开放标签托法替布5mg每日两次联合安慰剂(撤甲氨蝶呤组)或联合继续甲氨蝶呤(继续甲氨蝶呤组),使用相同胶囊掩蔽。
主要发现
- 共180例患者随机分组,90例接受托法替布5mg每日两次+安慰剂,89例接受托法替布+甲氨蝶呤(1例因随机化错误未治疗)。
- 不良事件、因不良事件停药、特殊关注不良事件和实验室变化率两组总体相似,但肝酶升高在托法替布+甲氨蝶呤组更常见。
- 托法替布+安慰剂组90例中1例(1%)报告症状加重(记录为银屑病关节病)。
关键数值与推荐
- 共同主要终点为第6个月PASDAS和HAQ-DI较子研究基线的变化,分析所有随机且接受至少一剂子研究药物的患者。
- 未检验特定统计假设(优效性或非劣效性)。
临床怎么用
- 对于已稳定接受托法替布5mg每日两次联合甲氨蝶呤的银屑病关节炎患者,可考虑在密切监测下停用甲氨蝶呤,但需注意肝酶变化和症状 flare。
局限性
- 本研究未检验优效性或非劣效性假设,解释组间差异需谨慎。
- 开放标签托法替布治疗,仅安慰剂/甲氨蝶呤部分为盲法。
- 子研究仅纳入已完成托法替布治疗≥24个月且稳定的患者,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. This study evaluated the efficacy and safety of tofacitinib 5 mg twice daily monotherapy after methotrexate withdrawal. METHODS: OPAL Balance was an open-label, long-term extension study of tofacitinib in patients with psoriatic arthritis who participated in the OPAL Broaden and OPAL Beyond phase 3 studies. This 12-month, randomised, double-blind, placebo-controlled, methotrexate withdrawal substudy (50 centres, 14 countries) included patients from OPAL Balance who completed tofacitinib treatment for 24 months or more (≥3 months' stable tofacitinib 5 mg twice daily) and were receiving methotrexate (7·5-20 mg/week). Patients were blindly randomised (1:1) using interactive response technology and received open-label tofacitinib 5 mg twice daily with either placebo (tofacitinib 5 mg twice daily plus placebo group) or continued methotrexate (tofacitinib 5 mg twice daily plus methotrexate group). Patients were masked to placebo or methotrexate, with identical capsules used. Coprimary endpoints were changes from substudy baseline in psoriatic arthritis disease activity score (PASDAS) and health assessment questionnaire-disability index (HAQ-DI) at month 6 in all randomised patients with one or more substudy drug dose. Safety was assessed throughout. No specific statistical hypothesis (either superiority or non-inferiority) was tested. The study (OPAL Balance) is registered with ClinicalTrials.gov (NCT01976364) and is complete. FINDINGS: Between Oct 30, 2017, and May 20, 2019, 180 patients from OPAL Balance who were eligible for the substudy were randomly assigned to treatment (90 patients received tofacitinib 5 mg twice daily plus placebo and 89 patients assigned to tofacitinib plus methotrexate; one patient was not treated because of randomisation error). At month 6, least squares mean (LSM) changes in PASDAS were 0·23 (SE 0·08) for tofacitinib 5 mg twice daily plus placebo and 0·14 (0·08) for tofacitinib 5 mg twice daily plus methotrexate (treatment difference LSM 0·09 [95% CI -0·13 to 0·31]), and changes in HAQ-DI were 0·04 (0·03) and 0·02 (0·03), respectively (treatment difference 0·03 [-0·05 to 0·10]). Rates of adverse events, discontinuations because of adverse events, adverse events of special interest, and laboratory changes were generally similar between treatment groups, although liver enzyme elevations were more common with tofacitinib 5 mg twice daily plus methotrexate than tofacitinib 5 mg twice daily plus placebo. Flares of worsening symptoms was reported in one (1%) of 90 patients in the tofacitinib 5 mg twice daily plus placebo group (recorded as psoriatic arthropathy). INTERPRETATION: Some patients with psoriatic arthritis who are stable on tofacitinib 5 mg twice daily with background methotrexate might be able to discontinue methotrexate without clinically meaningful changes in disease activity and safety. FUNDING: Pfizer Inc.
引用
- Nash P, Mease PJ, Fleishaker D, et al. Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance. Lancet Rheumatol. 2020. PMID: 38273637. doi:10.1016/S2665-9913(20)30339-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。